Ozempic, which contains semaglutide GLP-1, is primarily used for blood sugar control in type 2 diabetes patients but also has significant weight loss benefits
However, the simultaneous GLP-1 and GIP agonism appears to counterbalance this effect while still allowing glucagon to drive its metabolic benefits
A 3-week multicentre randomized controlled trial (ALADIN Study)
Conclusion: The outlook for state Medicaid coverage of GLP-1 AOMs While 13 state Medicaid programs covered at least one GLP-1 approved for weight management as of August 2024, states subsequently reversed course: California, New Hampshire, Pennsylvania, and South Carolina recently withdrew coverage
Endocrinology 119 , 14671475 (1986)
This breakthrough enables researchers to target specific genetic factors, paving the way for personalized, gene-focused therapies